MedPath
EMA Product

Luminity

Product approved by European Medicines Agency (EU)

Basic Information

Luminity

Regulatory Information

EMEA/H/C/000654

Authorised

September 20, 2006

July 27, 2006

17

June 28, 2023

Company Information

Ireland

Atlantic Avenue Westpark Business Campus Shannon Co. Clare

Lantheus EU Ltd.

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication This medicinal product is for diagnostic use only. Luminity is an ultrasound contrast-enhancing agent for use in patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress.

Overview Summary

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

© Copyright 2025. All Rights Reserved by MedPath